Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more
Jw Life Science Corp (234080) - Net Assets
Latest net assets as of September 2025: ₩214.86 Billion KRW
Based on the latest financial reports, Jw Life Science Corp (234080) has net assets worth ₩214.86 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩310.01 Billion) and total liabilities (₩95.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩214.86 Billion |
| % of Total Assets | 69.31% |
| Annual Growth Rate | 10.31% |
| 5-Year Change | 51.78% |
| 10-Year Change | N/A |
| Growth Volatility | 6.73 |
Jw Life Science Corp - Net Assets Trend (2015–2024)
This chart illustrates how Jw Life Science Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jw Life Science Corp (2015–2024)
The table below shows the annual net assets of Jw Life Science Corp from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩200.44 Billion | +25.75% |
| 2023-12-31 | ₩159.39 Billion | +13.58% |
| 2022-12-31 | ₩140.33 Billion | +6.72% |
| 2021-12-31 | ₩131.49 Billion | -0.43% |
| 2020-12-31 | ₩132.06 Billion | +7.70% |
| 2019-12-31 | ₩122.62 Billion | +12.23% |
| 2018-12-31 | ₩109.26 Billion | +7.01% |
| 2017-12-31 | ₩102.10 Billion | +13.07% |
| 2016-12-31 | ₩90.30 Billion | +9.02% |
| 2015-12-31 | ₩82.83 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jw Life Science Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 788.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩132.42 Billion | 66.06% |
| Other Components | ₩68.02 Billion | 33.94% |
| Total Equity | ₩200.44 Billion | 100.00% |
Jw Life Science Corp Competitors by Market Cap
The table below lists competitors of Jw Life Science Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Monument Mining Limited
PINK:MMTMF
|
$76.06 Million |
|
Administradora Americana de Inversiones S.A.
SN:AAISA
|
$76.07 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
$76.07 Million |
|
Pharmaniaga Bhd
KLSE:7081
|
$76.08 Million |
|
Pyridam Farma Tbk
JK:PYFA
|
$76.03 Million |
|
Interactive Digital Technologies
TWO:6486
|
$76.03 Million |
|
Kernel Holding S.A
PINK:KARNF
|
$76.01 Million |
|
Prime Office A/S
CO:PRIMOF
|
$76.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jw Life Science Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 159,393,121,640 to 200,444,748,390, a change of 41,051,626,750 (25.8%).
- Net income of 43,987,530,990 contributed positively to equity growth.
- Dividend payments of 7,742,277,000 reduced retained earnings.
- Other factors increased equity by 4,806,372,760.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩43.99 Billion | +21.94% |
| Dividends Paid | ₩7.74 Billion | -3.86% |
| Other Changes | ₩4.81 Billion | +2.4% |
| Total Change | ₩- | 25.75% |
Book Value vs Market Value Analysis
This analysis compares Jw Life Science Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.02x to 1.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩6447.98 | ₩13000.00 | x |
| 2018-12-31 | ₩6899.94 | ₩13000.00 | x |
| 2019-12-31 | ₩7743.54 | ₩13000.00 | x |
| 2020-12-31 | ₩8340.03 | ₩13000.00 | x |
| 2021-12-31 | ₩8491.82 | ₩13000.00 | x |
| 2022-12-31 | ₩9062.74 | ₩13000.00 | x |
| 2023-12-31 | ₩10293.69 | ₩13000.00 | x |
| 2024-12-31 | ₩12944.82 | ₩13000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jw Life Science Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.94%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.77%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.62x
- Recent ROE (21.94%) is above the historical average (15.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 15.53% | 10.21% | 0.70x | 2.17x | ₩4.58 Billion |
| 2016 | 16.79% | 11.46% | 0.69x | 2.13x | ₩6.13 Billion |
| 2017 | 16.44% | 11.69% | 0.72x | 1.94x | ₩6.57 Billion |
| 2018 | 14.48% | 10.19% | 0.77x | 1.84x | ₩4.90 Billion |
| 2019 | 17.89% | 12.89% | 0.85x | 1.64x | ₩9.68 Billion |
| 2020 | 12.77% | 9.19% | 0.84x | 1.65x | ₩3.66 Billion |
| 2021 | 9.82% | 7.60% | 0.77x | 1.67x | ₩-235.58 Million |
| 2022 | 10.66% | 7.92% | 0.75x | 1.80x | ₩928.02 Million |
| 2023 | 17.66% | 13.61% | 0.81x | 1.61x | ₩12.20 Billion |
| 2024 | 21.94% | 19.77% | 0.68x | 1.62x | ₩23.94 Billion |
Industry Comparison
This section compares Jw Life Science Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jw Life Science Corp (234080) | ₩214.86 Billion | 15.53% | 0.44x | $76.03 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |